Sign in

You're signed outSign in or to get full access.

Yacov Shamash

Director at KEY TRONIC
Board

About Yacov A. Shamash

Yacov A. Shamash (age 75) has served on Key Tronic Corporation’s Board since 1989. He is a Professor of Electrical and Computer Engineering at Stony Brook University, previously serving as Vice President of Economic Development (2001–2019) and Dean of Engineering and Applied Sciences (1992–2015). He holds a B.S. in electrical engineering and a Ph.D. in Control Systems from Imperial College London. The Board deems him qualified based on professional and management experience, public company board service, and education .

Past Roles

OrganizationRoleTenureCommittees/Impact
Stony Brook UniversityProfessor, Electrical & Computer EngineeringOngoingAcademic and tech leadership
Stony Brook UniversityVice President of Economic Development2001–2019Regional innovation, industry collaboration
Stony Brook UniversityDean of Engineering & Applied Sciences1992–2015Expanded engineering programs; applied research orientation
Washington State UniversityChair, Electrical & Computer Engineering1985–1992Department leadership, curriculum oversight
NSF I/U CRC (Design of Analog/Digital Integrated Circuits)Director1989–1992University–industry cooperative research center leadership

External Roles

Company/OrganizationRolePublic/PrivateNotes
Applied DNA Sciences, Inc.DirectorPublicForensics/DNA authentication; potential technology adjacency
Comtech Telecommunications Corp.DirectorPublicCommunications/defense; industry adjacency
Softheon Inc.DirectorPrivateHealthcare technology platform
Advanced Convergence GroupDirectorPrivateTechnology-focused enterprise

Board Governance

  • Independence: The Board determined all directors are independent except the former CEO (Gates) and current CEO (Larsen); Shamash is independent under Nasdaq rules .
  • Committee assignments:
    • Compensation and Administration Committee Chair (Shamash); members Bean, Kulkarni, Beranek; met 5 times in FY2025 .
    • Audit Committee member; chaired by Bean; members Klawitter, Kulkarni, Shamash, Beranek; met 12 times in FY2025 .
    • Governance and Nominating Committee member; chaired by Bean; members Klawitter, Kulkarni, Shamash, Beranek; met 2 times in FY2025 .
  • Attendance: Board met 7 times in FY2025; each director attended at least 85% of Board meetings and at least 84% of committee meetings; all nominees attended the 2024 Annual Meeting .
  • Executive sessions: Independent directors held executive sessions at two of the five Board meetings in FY2025 .
  • Board leadership and risk oversight: CEO and Chair roles are separated; committees oversee financial reporting/internal controls (Audit), compensation risk (Compensation), and board composition/governance (Governance & Nominating) .

Fixed Compensation

ComponentFY2025 AmountNotes
Annual cash retainer (non-Chair)$81,000Voluntary 10% temporary reduction effective May 18, 2025 for all non-employee directors
Fees earned/paid in cash – Shamash$81,000Reported in Non-Employee Director Compensation Table

Performance Compensation

Award TypeGrant DateQuantity/ValueVestingMetrics
RSUs (non-employee director grant)9/3/20248,869 units; $40,000 fair valueVest on first anniversary of grantDirector-specific performance metrics not disclosed; company ceased SAR grants and moved to RSUs beginning FY2025
Long-Term Non-Equity Incentive Awards (Directors)Ongoing under planNot individually quantifiedAs per planNon-employee directors receive long-term non-equity incentive awards; metrics not specified in proxy
  • Compensation Committee consulting: Engaged Total Compensation Solutions (TCS) and Milliman for executive and director compensation and peer group selection; neither provided other services (reducing consultant conflicts) .
  • Clawback policy: Adopted per SEC/Nasdaq for executive officers; applies to incentive-based compensation upon accounting restatement; not specified for directors .

Other Directorships & Interlocks

External CompanySectorPotential Interlock Considerations
Applied DNA Sciences, Inc.Authentication/forensicsNo related-party transactions disclosed with KTCC
Comtech Telecommunications Corp.Communications/defenseNo related-party transactions disclosed with KTCC
Softheon Inc.; Advanced Convergence GroupTechnologyNo related-party transactions disclosed with KTCC

Expertise & Qualifications

  • Technical and academic leadership across engineering, applied research, and university–industry collaboration, including directing an NSF I/U CRC focused on analog/digital IC design .
  • Broad governance exposure via multiple public company boards in technology sectors (Applied DNA Sciences, Comtech Telecommunications) .
  • Educational credentials: B.S. in electrical engineering; Ph.D. in Control Systems, Imperial College London .

Equity Ownership

ItemAmountNotes
Total beneficial ownership (shares)51,195Includes 1,100 shares owned directly by his daughter
Shares outstanding (record date)10,773,774As of September 9, 2025
Ownership as % of shares outstanding~0.48%Computed from 51,195 / 10,773,774
Outstanding/unvested director RSUs (as of 6/28/2025)8,869Non-employee director grant from 9/3/2024
Hedging/pledgingProhibitedInsider Trading Policy prohibits short sales, options, hedging, margin accounts, and pledging

Governance Assessment

  • Strengths:
    • Long-tenured independent director with deep technical and academic credentials and multiple public-company directorships, bringing diversified governance perspective .
    • Chairs Compensation Committee and serves on Audit and Governance Committees, indicating high engagement and board trust; attendance thresholds met .
    • Compensation consultant independence (no other services); shift from SARs to RSUs reduces risk and aligns with prevailing governance best practices .
    • Insider Trading Policy bans hedging/pledging; CEO/Chair split supports oversight; independent director executive sessions held .
  • Alignment:
    • Meaningful personal shareholding (51,195 shares) plus standard director RSUs supports skin-in-the-game; Section 16 compliance reported for FY2025 .
  • Potential Watch Items:
    • Multiple external directorships may increase time commitments; however, attendance metrics indicate adequate engagement .
    • Long-term non-equity incentive awards for directors are noted without disclosed performance metrics; monitor for clarity in future proxies .
    • No related-party transactions disclosed involving Shamash; continue monitoring for interlocks with Applied DNA Sciences or Comtech, though none disclosed in FY2025 .

RED FLAGS: None disclosed specific to Shamash in FY2025. No related-party transactions, no pledging/hedging, and no delinquent Section 16 reports reported .